# WIA-BIO-003: Security & Privacy Specification

## Version 1.0 | 2025-01-15

## Overview

Biomarker data protection requires safeguarding genetic information, clinical outcomes, and longitudinal patient data while enabling research and clinical decision-making.

## Patient Data Protection

### De-identification for Biomarker Studies

**HIPAA Safe Harbor + Biomarker-Specific:**
```
Standard Removals:
1-18. Standard HIPAA identifiers

Biomarker-Specific:
19. Rare biomarker values (unique fingerprints)
20. Exact allele frequencies for rare variants  
21. Precise measurement values (bin if unique)
22. Batch/lot numbers if traceable to individual
```

### Consent for Biomarker Research

**Tiered Consent Model:**
```json
{
  "consentId": "BIOMARKER_CONSENT_001",
  "permissions": {
    "clinicalTesting": true,
    "biomarkerDiscovery": true,
    "dataSharing": {
      "institutionalResearch": true,
      "publicDatabases": false,
      "commercialUse": false
    },
    "futureContact": {
      "newFindings": true,
      "additionalStudies": false
    },
    "sampleStorage": {
      "duration": "10 years",
      "futureUse": true
    }
  }
}
```

## Data Security

### Encryption Standards

**Data at Rest:**
- AES-256 encryption for all biomarker databases
- Separate encryption keys for identifiable vs. coded data

**Data in Transit:**
- TLS 1.3 for all API communications
- VPN for site-to-site data transfer

### Access Control

| Role | Biomarker Discovery Data | Clinical Biomarker Results | Patient Identifiers |
|------|-------------------------|----------------------------|---------------------|
| **Researcher** | De-identified, Read | No access | No access |
| **Lab Technician** | No access | Read/Write (coded ID) | No access |
| **Clinician** | No access | Read (patient-linked) | Read |
| **Data Curator** | De-identified, Read/Write | No access | No access |
| **Administrator** | All data types | All data types | Read only |

## Regulatory Compliance

### Clinical Validation Data Retention

**Requirements:**
- Raw data: 3 years post-validation
- Analyzed data: 10 years minimum
- Regulatory submissions: Permanent

### Privacy Impact Assessment

**Required for:**
- New biomarker discovery studies (>500 participants)
- Multi-site data sharing
- Commercial biomarker development

---

**Document Version:** 1.0
**Last Updated:** 2025-01-15
**Maintained by:** WIA BIO Working Group
**License:** Apache 2.0
